Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Vedotin + Pembro vs. Chemo in Previously Untreated la/mUC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Thomas Powles
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Thomas Powles
Login to view comments.
Click here to Login
Genitourinary